Tamoxifen and endometrial neoplasia

Clinical Obstetrics and Gynecology

Volumn 39, Issue 3, 1996, Pages 629-640

  Barakat, Richard R ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SCREENING; DRUG EFFECT; ENDOMETRIUM CANCER; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; POLYP; REVIEW;

BREAST NEOPLASMS; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS; TAMOXIFEN; UTERINE NEOPLASMS;

EID: 0029747236     PISSN: 00099201     EISSN: None     Source Type: Journal    
DOI: 10.1097/00003081-199609000-00012     Document Type: Review

References (36)

1. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 1985;69:237-238.
2. Hardell L. Tamoxifen as risk factor for carcinoma of corpus uteri (letter). Lancet. 1988;3:563.
3. Neven P, Muylder X, Van Belle Y, et al. Tamoxifen and the uterus and endometrium (letter). Lancet. 1989;1:375.
4. Fornander T, Cedermark B, Mattsson A, et al. Adjuvant tamoxifen in early breast cancer: occurrence of new primary cancers. Lancet. 1989;21:117-120.
5. Atlante G, Pozzi M, Vincenzoni C, et al. Four case reports presenting new acquisitions on the association of breast and endometrial cancer. Gynecol Oncol. 1990;37:378-380.
6. Mathew A, Chabon AB, Kabakow B, et al. Endometrial carcinoma in five patients with breast cancer on tamoxifen therapy. NY State J Med. 1990;90:207-208.
7. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol. 1990;39:82-84.
8. Magriples U, Naftolin F, Schwartz PE, et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 1993;11:485-490.
9. Lahti E, Blanco G, Kauppila A, et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 1993;81:660-664.
10. Seoud MA-F, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 1993;82:165-169.
11. Van Leeuwen FE, Benraadt J, Coebergh JWW, et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet. 1994;343:448-452.
12. Fisher B, Costantino JP, Redmond CK, et al. Endometrial cancer in tamoxifen-treated breast cancer patients: findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst. 1994;86:527-537.
13. Barakat RR, Wong G, Curtin JP, et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol. 1994;55:164-168.
14. Assikis VJ, Jordan VC. Gynecologic effects of tamoxifen and the association with endometrial carcinoma. Int J Gynecol Obstet. 1995;49:241-257.
15. Satyaswaroop PG, Zaino RJ, Mortel R. Estrogen-like effects of tamoxifen on human endometrial carcinoma transplanted into nude mice. Cancer Res. 1984;44:4006-4010.
16. Gottardis MM, Robinson SP, Satyaswaroop PG, et al. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 1988;48:812-815.
17. Boccardo F, Bruzzi P, Rubagotti A, et al. Estrogen-like action of tamoxifen on vaginal epithelium in breast cancer patients. Oncology. 1981;38:281-285.
18. Corley D, Rowe J, Curtis MT, et al. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol. 1992;79:111-116.
19. Neven P, De Muylder X, Van Belle Y, Vanderick G, De Muylder Y. Hysteroscopic follow up during tamoxifen treatment. Eur J Obstet Gynecol Reprod Biol. 1990;35:235-238.
20. Gal D, Kopel S, Bashevkin M, et al. Oncologic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol. 1991;42:120-123.
21. Gibson LE, Barakat RR, Venkatraman ES, et al. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. The Cancer Journal. 1996;2:35-38.
22. Hacker NF, Moore JG, eds. Essentials of Obstetrics and Gynecology. 2nd ed. Philadelphia: WB Saunders Co, 1992:577.
23. Kedar RP, Bourne TH, Powles TJ, et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomised breast cancer prevention trial. Lancet. 1994;343:1318-1321.
24. National Cancer Institute. SEER Cancer Statistics Review 1973-1990. Document #932789. Bethesda, MD: National Cancer Institute, 1993.
25. Rutqvist LE, Johansson H, Signomklao T, et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst. 1995;87:645-651.
26. Wolf DM, Jordan VC. Gynecologic complications associated with long-term adjuvant tamoxifen therapy for breast cancer. Gynecol Oncol. 1992;45:118-128.
27. Elwood JM, Boyes DA. Clinical and pathological features and survival of endometrial cancer patients in relation to prior use of estrogens. Gynecol Oncol. 1980;10:173-187.
28. Silva EG, Tornos CS, Follen-Mitchell M. Malignant neoplasms of the uterine corpus in patients treated for breast carcinoma: the effects of tamoxifen. Int J Gynecol Pathol. 1994;13:248-258.
29. Fornander T, Hellstrom A-C, Moberger B. Descriptive clinicopathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst. 1993;85:1850-1855.
30. Steinberg KK, Thacker SB, Smith SJ, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA. 1991;265:1985-1990.
31. Barakat RR, Gilewski TA, Saigo PE, et al. The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: an interim analysis of a prospective study. Proc ASCO 1995:779. Abstract.
32. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1994;170:447-451.
33. Han XL, Liehr JG. Induction of covalent DNA adducts in rodents by tamoxifen. Cancer Res. 1992;52:1360-1363.
34. White IN, De Matteis F, Davies A, et al. Genotoxic potential of tamoxifen and analogues in female Fischer F344/n rats, DBA/2 and C57BL/6 mice and in human MCL-5 cells. Carcinogenesis. 1992;13:2197-2203.
35. Pongracz K, Pathak DN, Nakamura T, et al. Activation of the tamoxifen derivative metabolite E to form DNA adducts: comparison with the adducts formed by microsomal activation of tamoxifen. Cancer Res. 1995;55:3012-3015.
36. Barakat RR, Adhikari D, Saigo PE, O'Connor B, Banerjee D, Bertino JR. Mutation of c-Ki-ras in tamoxifen-associated endometrial carcinoma. Accepted for presentation, Society of Gynecologic Oncologists' Annual Meeting, 1996 (in press).